{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019019","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.321339+00:00","generated_at":"2026-06-08T03:12:31.209154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Capricor completes HOPE-3 enrollment; Q3 net loss $6.4M, cash $28.5M","bullets":["Completed targeted enrollment for HOPE-3 Phase 3 trial of CAP-1002 in Duchenne muscular dystrophy; interim futility analysis expected Q4 2023.","FDA affirmed alignment on HOPE-3 design; BLA submission planned supported by Cohort A results.","Q3 revenue $6.2M (from Nippon Shinyaku upfront recognition) vs $1.6M prior year; net loss $6.4M flat YoY.","Cash $28.5M at Sept 30; subsequent $23M registered direct offering with Nippon Shinyaku extends runway into 2025.","Appointed Michael Kelliher (Amgen/Horizon) to Board of Directors; advancing StealthX exosome platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019019","json":"https://secwatch.observer/filing/0001558370-23-019019.json","markdown":"https://secwatch.observer/filing/0001558370-23-019019.md","text":"https://secwatch.observer/filing/0001558370-23-019019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/0001558370-23-019019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/capr-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:12:31.209154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9171db25be4101de5c8d96fbbbe79d45ba318a3","claim":"CAPRICOR THERAPEUTICS, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/0001558370-23-019019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}